thalidomide-o-c6-nh2 tfa

Thalidomide-O-C6-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate used in the PROTAC dTAG-13, a degrader of FKBP12F36V and BET[1].

Thalidomide-O-amido-C6-NH2 TFA (Cereblon Ligand-Linker Conjugates 11 TFA) is a synthesized E3 ligase ligand-linker conjugate comprising a Thalidomide-based cereblon ligand and a linker.

Thalidomide-O-amido-C6-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate, integrating a Thalidomide-based cereblon ligand with a linker, suitable for PROTAC synthesis.

Thalidomide-NH-PEG1-NH2 hydrochloride (4-[(2-(2-Aminoethoxy)ethyl)amino]-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione HCl) is a synthetic E3 ligase ligand-linker conjugate that incorporates the Thalidomide-based cereblon ligand and a linker[1].

Thalidomide-NH-C2-PEG3-OH (H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-4-[[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethyl]amino]-) is an E3 ligase ligand-linker conjugate.

Thalidomide-O-CH2CONH-CH2COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based CRBN ligand and linker used in PROTAC technology.

Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride, incorporating an E3 ligase ligand and a linker, can be used as an immunomodulator for the treatment of cancer.

Boc-NH-O-C1-NHS ester, an alkyl ether-based PROTAC linker, is utilized in PROTAC synthesis.

Thalidomide-O-amido-C3-NH2 TFA (Cereblon Ligand-Linker Conjugates 16 TFA) is a synthesized E3 ligase ligand-linker conjugate incorporating a Thalidomide-based cereblon ligand and a linker used in PROTAC technology.

Thalidomide-O-amido-PEG-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate, incorporating a Thalidomide-based cereblon ligand and a linker. This compound is used in the synthesis of PROTACs.

Thalidomide-O-amido-C4-NH2 TFA (E3 ligase Ligand-Linker Conjugates 19 TFA) is a synthesized compound that functions as an E3 ligase ligand-linker conjugate.

Thalidomide-O-amido-PEG3-C2-NH2 TFA (Cereblon Ligand-Linker Conjugates 3 (TFA)) is a synthesized E3 ligase ligand-linker conjugate incorporating a Thalidomide-based cereblon ligand and a 3-unit PEG linker, used in PROTAC technology.

Thalidomide-linker 9 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

Thalidomide-NH-C4-NH-Boc is a synthesized conjugate used in PROTAC technology, combining a Thalidomide-based cereblon ligand with a linker.

Thalidomide-O-amido-PEG2-C2-NH2 TFA (E3 Ligase Ligand-Linker Conjugates 24 TFA) is a synthesized E3 ligase ligand-linker conjugate incorporating the Thalidomide-based cereblon ligand and a 2-unit PEG linker, utilized in PROTAC technology.

Pomalidomide-C6-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based CRBN ligand and linker used in PROTAC technology.

Thalidomide-O-COOH (Cereblon ligand 3) is a Thalidomide-based Cereblon ligand utilized for recruiting the CRBN protein and can be linked to a protein ligand via a linker to create PROTACs.

Thalidomide-NH-CH2-COOH ((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)glycine) is a synthesized E3 ligase ligand-linker conjugate containing a Thalidomide-based cereblon ligand and a linker.

Thalidomide-O-C6-NH2 hydrochloride (4-((6-aminohexyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione hydrochloride) is a synthesized E3 ligase ligand-linker conjugate.

Deoxy-thalidomide-Pip-C-PIP-boc, a conjugate of E3 ligase ligand and linker, comprises Thalidomide and the corresponding Linker. It functions as a Cereblon ligand to recruit CRBN protein and acts as a crucial intermediate in synthesizing complete PROTAC molecules.

Thalidomide-O-amido-C3-PEG3-C1-NH2 is a synthesized conjugate compound serving as an E3 ligase ligand-linker, featuring a cereblon ligand based on Thalidomide and a 3-unit PEG linker, specifically designed for use in PROTAC technology.

Thalidomide-O-C7-NH2 is a synthesized conjugate compound comprising an E3 ligase ligand-linker conjugate. This compound incorporates a cereblon ligand based on Thalidomide and a linker that is commonly employed in PROTAC technology.

Thalidomide-NH-(CH2)2-NH2 TFA, an alkyl-modified derivative of Thalidomide, functions as a Cereblon ligand to recruit CRBN proteins and serves as a crucial intermediate in the synthesis of CRBN-based PROTAC molecules targeting the SHP2 protein.

Thalidomide-NH-PEG4-Ms is a conjugate that consists of a cereblon ligand based on Thalidomide and a linker molecule, which serves as a ligand-linker moiety for E3 ligase. This conjugate is specifically designed as a degrader for PROTAC BCL-XL, known as XZ739.

2-(2-(6-Chlorohexyloxy)ethoxy)ethanamine hydrochloride [catalog number: T64585] is a valuable organic compound for life sciences research.

Thalidomide-O-amido-C8-NH2 hydrochloride is a synthetic conjugate of an E3 ligase ligand-linker, which combines a cereblon ligand derived from Thalidomide and a linker. It can be utilized in the synthesis of PROTACs[1].

Thalidomide-NH-C10-COOH (compound 6b) is a synthetic E3 ligase ligand-linker conjugate, combining the Thalidomide-based von Hippel-Lindau (VHL) ligand with a linker commonly used in PROTAC technology. [1]

Pomalidomide-C2-amido-(C1-O-C5-O-C1)2-COOH is a chemically synthesized E3 ligase ligand-linker conjugate, incorporating the cereblon ligand from Pomalidomide and a linker used in PROTAC technology. It facilitates targeted protein degradation by modulating E3 ligase activity, thereby enabling the selective elimination of specific proteins of interest.

Thalidomide-O-PEG2-propargyl (E3 Ligase Ligand-Linker Conjugates 32) is a chemical compound that has been synthesized as a conjugate of an E3 ligase ligand and a linker. It incorporates the cereblon ligand based on Thalidomide, along with a 2-unit PEG linker. This compound is specifically designed for use in PROTAC technology, which utilizes ligand-induced protein degradation [1].

Thalidomide-NH-PEG7 is a synthesized conjugate of an E3 ligase ligand and linker, intended for use in antibody-drug conjugates (ADCs). It can be attached to a protein ligand via a linker to form PROTAC iRucaparib-AP6, a highly selective degrader of PARP1[1].

Thalidomide-O-amido-C4-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate, combines the cereblon ligand derived from Thalidomide with a linker and is commonly used in the synthesis of PROTACs[1].

BnOH-NH-bis-(C2-S)-propane-O-isoprene ester (PROTAC Linker 29) is an alkyl ether-based linker used mainly for synthesizing PROTACs.

Thalidomide-NH-C10-NH2 hydrochloride, a thalidomide-derived cereblon ligand, facilitates CRBN protein recruitment and, when conjugated with a linker, forms PROTACs [1].

Thalidomide-5-NH-PEG1-NH2 hydrochloride is a Thalidomide-based cereblon ligand designed for CRBN protein recruitment. It facilitates the formation of PROTAC molecules by linking to target protein ligands, such as THAL-SNS-032, via a connector.

Thalidomide-O-amido-C6-NH2 (Cereblon Ligand-Linker Conjugates 11) is a Thalidomide-based synthetic E3 ligase ligand-linker conjugate, consisting of a cereblon ligand and a linker, used in the production of PROTACs (proteolysis-targeting chimeras).

Thalidomide-5-O-C2-NH2 hydrochloride, a Thalidomide-based cereblon ligand, facilitates the recruitment of CRBN protein and can be conjugated via a linker to form PROTACs [1].

Thalidomide-5-O-C4-NH2 hydrochloride, a cereblon ligand derived from Thalidomide, facilitates the recruitment of CRBN protein. It can be tethered to a ligand for protein recruitment through a linker, enabling the formation of PROTACs [1].

PROTAC PTPN2 degrader-2 (example 187B) TFA is a potent Protein Tyrosine Phosphatase Non-receptor Type 2 (PTPN2) degrader with potential applications in cancer and metabolic disease research [1].

Thalidomide-NH-PEG2-C2-NH-Boc, a synthesized E3 ligase ligand-linker conjugate, combines the cereblon-targeting Thalidomide ligand with a PEG linker for the synthesis of dBRD9 (compound 6). This selective BRD9 probe PROTAC degrader is utilized in researching BAF complex biology.

Thalidomide-O-amido-C3-NH2 is a synthesized E3 ligase ligand-linker conjugate that combines a cereblon ligand derived from Thalidomide with a linker used in PROTAC technology.

Thalidomide-NH-C6-NH-Boc is a synthesized E3 ligase ligand-linker conjugate containing a cereblon ligand derived from Thalidomide and a linker used in the synthesis of MI-389 [compound 22], a highly effective phthalimide PROTAC degrader developed from the multi-targeted receptor tyrosine kinase inhibitor sunitinib.

Thalidomide-NH-PEG4-COOH is a conjugate comprising an E3 ligase ligand-linker, utilized in the synthesis of dCBP-1. dCBP-1 itself functions as a powerful and selective heterobifunctional degrader targeting p300 CBP.

Thalidomide-O-amido-C3-COOH is a synthesized conjugate of an E3 ligase ligand-linker compound that combines a cereblon ligand (derived from Thalidomide) with a linker commonly employed in PROTAC technology.

Thalidomide-O-amido-PEG3-C2-NH2 TFA, a synthesized E3 ligase ligand-linker conjugate, combines the cereblon ligand based on Thalidomide and a 2-unit PEG linker for use in PROTAC technology[1].

Ph-Bis(C1-N-(C2-NH-Boc)2) is a versatile alkyl chain-derived linker used in the synthesis of PROTACs [1].

Thalidomide-O-amido-PEG4-azide is a polyethylene glycol (PEG) derivative used as a linker in the synthesis of Proteolysis Targeting Chimeras (PROTACs) [1].

Thalidomide-O-PEG4-amine is a PEG-based PROTAC linker used in the synthesis of PROTACs [1].

Thalidomide-NH-C6-NH2 is a synthetic conjugate designed as an E3 ligase ligand-linker, comprising a Thalidomide-based cereblon ligand connected to a specific linker used in PROTAC technology[1].